TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02100618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples will be collected from all subjects at Year 6.5

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood samples will be collected from all subjects at Year 6.5
Study: NCT02517333

Intervention type: OTHER
Group type: OTHER
Intervention: EPIC Club
Description: Weekly exercise gym sessions (1-2 times weekly) for 45-60 mins each session. Participants will start with a warm-up of 30 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. Gym sessions aim to involve bursts of high-intensity and monitoring of heart rate (potentially with wrist activity monitors with heart rate monitoring and accelerometers) to identify level of physical activity intensity. Participants will also have the opportunity to engage in 'Have a go' sports days run by the Oxfordshire Sports Partnership.
Study: NCT03282175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Each training session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group did not receive any treatment.
Study: NCT01901133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: Oral
Study: NCT01668979

Intervention type: DEVICE
Intervention: new system to detect Near Falls
Description: We will invite healthy older adults with a history of falls to try the new system and assess whether the new system can induce, detect and quantify Near Fall episodes
Study: NCT04223921

Intervention type: OTHER
Intervention: Comparison of patient's medicines
Description: Comparison of patient's medicines:~* between patient's discharge from hospital and one month after this discharge (acute geriatric care unit)~* between patient's admission and discharge from hospital (acute geriatric care unit
Study: NCT01888718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine Hydrochloride
Description: Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine Hydrochloride
Description: Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg
Study: NCT00752570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 386
Description: AMG 386 (10 mg/kg QW) will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 386 Placebo
Description: AMG 386 placebo QW will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.~FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.~FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFIRI
Description: Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.~FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.~FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest.
Study: NCT03807505

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus nerve block
Description: An interscalene brachial plexus nerve block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: An erector spinae plane block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
Study: NCT01910558

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-cyclodextrin and digestible starch
Description: Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 3 gram alpha-cyclodextrin and 3 gram of starch

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-cyclodextrin
Description: Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams alpha-cyclodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Digestible starch
Description: Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams digestible starch
Study: NCT03271619

Intervention type: OTHER
Intervention: Surface current measurement
Description: Measurement of surface current between electrodes placed on the chest wall during defibrillation

Intervention type: OTHER
Intervention: Surface current measurement
Description: Measurement of surface current between electrodes placed on the chest wall during defibrillation
Study: NCT04346303

Intervention type: OTHER
Group type: OTHER
Intervention: Short-term Interactive Video Games
Description: 1. Collect basic information through a structured questionnaire, which includes basic information, disease status, life style and other related information.~2. Three data collections were performed, namely the baseline period (T0) and the pre-program (T1) two weeks later. Three weeks of intervention activities were provided twice a week, followed by a post-test ( post-program, T2).~3. After a total of six times mentioned above, each 60 minutes of interactive video game intervention, the patient completed the activity feedback form, reflecting the feelings and feedback of participating in the activity.
Study: NCT03323151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib 3 mg by mouth on days 1, 8 and 15 by mouth days 1-28 of a 28 day cycle. Dose may be escalated (Ixazomib 4 mg) dependent on dose-limiting toxicities. Note: Ixazomib dose will not be de-escalated but remain at 3 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib 4 mg by mouth on days 1, 8 and 15 of a 28 day cycle until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib 4 mg by mouth on days 1, 8 and 15 of a 28 day cycle until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ibrutinib 420 mg) or escalated (Ibrutinib 560 mg) dependent on dose-limiting toxicities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle until progression or unacceptable toxicity.
Study: NCT01625039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Employee wellness programme
Description: The experimental group was subjected to a wellness programme based on the principles of cognitive behaviour therapy (CBT) as well as weekly supervised exercise classes over six weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator (Once off educational session and educational materials)
Description: Once off educational session and educational materials
Study: NCT01258218

Intervention type: DEVICE
Intervention: Implantation of an Accent MRI device
Description: Implantation of an Accent MRI device
Study: NCT01397487

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blastomere biopsy
Description: The blastomere biopsy will be done after 72 hours of embryo culture. An inverted microscope Olympus IX70 with a heated stage will be used to perform the biopsy. The micromanipulation for the blastomere extraction will be made with a micropipette MBB-FP-M-30 (Humagen).
Study: NCT04548154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proximal Resistance Training
Description: Participants will be prescribed 5 categories of resistance exercises, and each category will have a series of exercises to select from. Two will target hip abduction, two will target trunk muscles, and one will target functional resistance training for the hip and trunk during walking-related tasks such as multi-directional resisted walking. Dosing will be based on guidelines for MS. Strengthening exercises will begin with 3 sets of 12-15 reps at 15 rep-max load (RM) and progress to 3 sets of 8-10 reps at 10-12 RM. Endurance exercises requiring a static hold will progress from 3 sets of 15-20 second holds to 30-second holds. Functional resistance will be dosed to improve muscular endurance: 3 sets of 15-20 reps based on form fatigue.
Study: NCT01667120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac 0.5mg/kg IV q8h x 72h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% normal saline 1ml/kg
Study: NCT01283217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS
Description: Docetaxel with S-1. S-1: Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP
Description: S-1 with cisplatin. S-1 : Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
Study: NCT01394991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 450 IU/kg once a week
Description: 450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg 3 times a week
Description: 150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 450 IU/kg once a week (QW)
Description: 450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg 3 times a week (TIW)
Description: 150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
Study: NCT01031043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol
Description: Taking part in this research study is voluntary. Patient may choose not to take part in this research study or may withdraw consent at any time. Their choice will not at any time affect the commitment of the health care providers to administer care. If the patient decides not to participate or withdraw from the study there will be no penalty or loss of benefits to which they are otherwise entitled.
Study: NCT03354299

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coconut milk
Description: 50 cc of coconut milk supplementation plus 25 gram sugar (pudding) was given to cirrhosis patients as late night snack

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: coconut milk
Description: 50 cc of coconut milk supplementation plus 25 gram sugar (pudding) was given to cirrhosis patients as late night snack
Study: NCT03524820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administration of drug
Study: NCT02479529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Administration and weaning of norepinephrine is based on dynamic arterial elastance

Intervention type: DRUG
Group type: OTHER
Intervention: Norepinephrine
Description: The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure, cardiac output), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
Study: NCT03608020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMX-001
Description: Manganese butoxyethyl pyridyl porphyrin

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Brain Radiation Therapy
Description: Whole Brain Radiation Therapy per standard of care.
Study: NCT03754738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon guide catheter
Description: Use a balloon guide catheter in the mechanical thrombectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-balloon guide catheter
Description: Use a non-balloon guide catheter in the mechanical thrombectomy
Study: NCT03031028

Intervention type: OTHER
Group type: OTHER
Intervention: ketogenic diet
Description: Ketogenic Diet is a high fat, low carbohydrate diet.
Study: NCT04757558

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC video-stylet
Description: Patients will be randomly assigned two group 40 patients each, C-MAC-VS group (VS group) (Karl Storz GmbHand Co.KG, Germany), and control group (C group). This will be done using a closed envelope technique using a computer-generated block randomization method.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Patients will be randomly assigned two group 40 patients each, C-MAC-VS group (VS group) (Karl Storz GmbHand Co.KG, Germany), and control group (C group). This will be done using a closed envelope technique using a computer-generated block randomization method.
Study: NCT06143761

Intervention type: DRUG
Intervention: PD-1 inhibitor+carboplatin+albumin-bound paclitaxel
Description: A comparative evaluation of patient prognosis between those who received neoadjuvant chemoimmunotherapy-surgery treatment and those who underwent surgery alone.
Study: NCT03946657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalational anesthetic
Description: Oxygen/air (fraction of inspired oxygen (FiO2) of 0.40), inspiratory fresh gas flow of 2 L/min), sevoflurane (1 minimum alveolar concentration \[MAC\]) and remifentanil IV infusion (0.1-0.25 mcg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
Study: NCT03946657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous anesthetic
Description: Propofol infusion (4-8 mg/kg of total body weight/h), oxygen/air (FiO2 of 0.40; inspiratory fresh gas flow of 2 L/min) and remifentanil IV infusion (0.1-0.25 μg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
Study: NCT03174964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIg
Description: Patients will take a dose of 400mg/kg of IVIg 2 days before ET.
Study: NCT03199716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent mentors
Description: Parent mentors are to meet up with their assigned intervention group 4 times in 1 year and call the families monthly to document any diabetic complications
Study: NCT04511130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-401
Description: MT-401 (zedenoleucel) is an allogeneic multi-tumor-associated antigen (MultiTAA)-specific T cell product manufactured under Good Manufacturing Practice (GMP) using donor-derived T cells obtained from apheresis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-401
Description: MT-401 (zedenoleucel) is an allogeneic multi-tumor-associated antigen (MultiTAA)-specific T cell product manufactured under Good Manufacturing Practice (GMP) using donor-derived T cells obtained from apheresis.
Study: NCT00005305

Intervention type: OTHER
Intervention: No interventions - observational study
Study: NCT02748239

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDIAS 2 CT
Description: The MEDIAS 2 CT is a education program for the initiation of a conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Current CT program
Description: The Current CT program is currently used for the initiation of conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
Study: NCT02687113

Intervention type: DEVICE
Group type: OTHER
Intervention: CT/US fusion
Description: Fusion of pre-RFA cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
Study: NCT00565682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg
Description: etoricoxib 120 mg, tablet, orally, OD
Study: NCT03466840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The coronally advanced lingual flap
Description: : A full-thickness crestal incision is performed from the distal surface of the more distal tooth to retromolar pad and finishing with releasing incision. On the lingual side, a full-thickness muco-periosteal flap was elevated until reaching mylohyoid line. Then using a blunt instrument, it was localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. It is inserted into the inner part of the lingual flap about 5mm from the crest in an apical direction. The blunt instrument is inserted below the connective band, and with gentle traction in the coronal direction, this muscular insertion was detached from the lingual flap. Using a periodontal probe, the amount of advancement is measured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified periosteal releasing Incision
Description: A full-thickness muco-periosteal flap is reflected on the buccal side. Near the base of muco-periosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade, or a blunt instrument, with sweeping motion. This motion helps stretching the flap over the submucosa, thereby permitting the flap to be mobile.Using a periodontal probe the amount of advancement is measured.
Study: NCT01953510

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV10
Description: PCV10 includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and protein D is the main carrier protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV10
Description: PCV10 includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and protein D is the main carrier protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV10
Description: PCV10 includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and protein D is the main carrier protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV10
Description: PCV10 includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and protein D is the main carrier protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: PCV13 includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually linked to non-toxic diphtheria CRM197 carrier protein
Study: NCT02093377

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive servo-ventilation
Description: Adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia)
Study: NCT02818751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Patients being randomized to receive escitalopram.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients being randomized to receive placebo.
Study: NCT00684437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Focus group discussion and evaluation of various smoking risk informational messages. The focus group session should last about 1 hour and 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Focus group discussion and evaluation of various smoking risk informational messages. The focus group session should last about 1 hour and 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Focus group discussion and evaluation of various smoking risk informational messages. The focus group session should last about 1 hour and 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Focus group discussion and evaluation of various smoking risk informational messages. The focus group session should last about 1 hour and 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires taking 15-30 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires taking 15-30 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires taking 15-30 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires taking 15-30 minutes to complete.
Study: NCT03069131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: twice daily administration of 1 tablet containing 550 mg of active rifaximin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily administration of 1 rifaximin placebo tablet